Cargando…
Polymyxin B therapy based on therapeutic drug monitoring in carbapenem-resistant organisms sepsis: the PMB-CROS randomized clinical trial
BACKGROUND: The appropriate administration regimen of polymyxin B is yet controversial. The present study aimed to explore the optimal dose of polymyxin B under therapeutic drug monitoring (TDM) guidance. METHODS: In China’s Henan province, 26 hospitals participated in a randomized controlled trial....
Autores principales: | Liu, Shaohua, Wu, Ying, Qi, Shaoyan, Shao, Huanzhang, Feng, Min, Xing, Lihua, Liu, Hongmei, Gao, Yanqiu, Zhu, Zhiqiang, Zhang, Shuguang, Du, Yuming, Lu, Yibin, Yang, Jing, Chen, Pingyan, Sun, Tongwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262552/ https://www.ncbi.nlm.nih.gov/pubmed/37312218 http://dx.doi.org/10.1186/s13054-023-04522-6 |
Ejemplares similares
-
Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study
por: Zhang, Xiaojuan, et al.
Publicado: (2021) -
Evaluation of polymyxin B AUC/MIC ratio for dose optimization in patients with carbapenem-resistant Klebsiella pneumoniae infection
por: Wang, Peile, et al.
Publicado: (2023) -
Pilot study on the effectiveness of the conventional CROS, the transcranial CROS and the BAHA transcranial CROS in adults with unilateral inner ear deafness
por: Hol, Myrthe K. S., et al.
Publicado: (2009) -
An area under the concentration–time curve threshold as a predictor of efficacy and nephrotoxicity for individualizing polymyxin B dosing in patients with carbapenem-resistant gram-negative bacteria
por: Yang, Jing, et al.
Publicado: (2022) -
Cros-Section Measurements in CHORUS
por: Artamonov, A V
Publicado: (2005)